Related by context. All words. (Click for frequent words.) 63 PK PD 62 pharmacokinetic pharmacodynamic 61 Pharmacokinetic 61 pharmacodynamic PD 60 preclinical efficacy 60 pharmacodynamic properties 60 pharmacokinetics PK 58 PHX# 58 Phase 1a clinical 58 pharmacokinetic PK 58 pharmacodynamic parameters 58 novel VDA molecule 58 multicenter Phase II 58 maximally tolerated dose 58 pharmacokinetics pharmacodynamics 57 pharmacodynamic markers 57 registrational Phase 57 safety tolerability pharmacokinetic 57 Initiated Phase 57 Cloretazine 57 Kahalalide F 57 retaspimycin 56 pharmacokinetic 56 pharmacodynamics 56 ongoing Phase 1b 56 CATIE AD 56 favorable pharmacokinetic 56 radiation dosimetry 56 mean ± SEM 56 Active Ulcerative Colitis 56 Elagolix 56 double blinded randomized 56 REMINYL ® 55 relapsed MM 55 liposomal formulation 55 PK PD modeling 55 Combination REOLYSIN R 55 ritonavir boosted 55 Pharmacodynamic 55 uricase 55 preclinical pharmacokinetic 55 placebo controlled dose escalation 55 HGS ETR2 55 pharmacokinetic PK study 55 Alfacell proprietary ribonuclease 55 Pharmacokinetic PK 55 Pharmacokinetics PK 55 phase IIIb 55 Randomized controlled 55 topically administered 55 demonstrated antitumor activity 55 pharmacodynamics PD 55 pharmacodynamic effects 55 confirmatory clinical 55 BRIM3 55 Bayer HealthCare Onyx Pharmaceuticals 55 CG# [003] 54 mGluR5 NAM 54 RE SURGE 54 dose escalation clinical 54 favorable pharmacokinetic profile 54 Primary endpoints 54 Quinamed 54 number NCT# ClinicalTrials.gov 54 randomized multicenter trial 54 ID NCT# 54 Pre RELAX AHF 54 Pivotal Phase III 54 STEALTH C 54 #beta estradiol 54 multicentre prospective 54 BOLDER II 54 fidaxomicin Phase 54 FOLOTYN ® 54 pharmacokinetic equivalence 54 lanthanum carbonate 54 GAMMAGARD 54 LAB CGRP 54 tolerability pharmacokinetics 54 thorough QT 54 dose proportionality 54 TMC# [002] 54 pharmacodynamic profiles 54 microRNA profiling 54 Phase IIIb clinical 54 galiximab 53 HEPLISAV TM 53 subcutaneously administered 53 rALLy trial 53 Phase III AFFIRM 53 randomized controlled multicenter 53 interferon gamma 1b 53 Genotypic 53 potent suppressor 53 phase Ib 53 Trofex 53 mg kg BID 53 Annamycin 53 crizotinib PF # 53 alvespimycin 53 MetaBase TM represents 53 neratinib 53 multicenter randomized controlled 53 inferential statistics 53 rxRNA 53 topoisomerase II inhibitor 53 echocardiographic parameters 53 NO# [002] 53 RECORD1 53 orally inhaled 53 Phase IIA 53 urocortin 2 53 GetGoal Phase III 53 Secretase 53 alemtuzumab MS 53 orally bioavailable 53 reactogenicity 53 proprietary polysaccharide 52 Aeolus Pharmaceuticals Announces 52 serum lipid 52 PENNVAX B 52 CELVAPAN H#N# 52 Onrigin TM 52 isatoribine 52 Phase IIb III 52 dasatinib Sprycel 52 Phase IIIb 52 Prostate AdenoCarcinoma Treatment 52 multicenter multinational 52 Omacetaxine 52 retrospective observational study 52 atazanavir ritonavir 52 CDK inhibitor 52 budesonide MMX 52 Phase 1a 52 multivariable Cox 52 Pharmacokinetic parameters 52 PRTX 52 viral kinetics 52 metabolite identification 52 GENASIS clinical 52 pharmacokinetic parameters 52 NSABP B 52 oral deforolimus 52 Solulin 52 NCIC CTG 52 melphalan prednisone 52 Phase Ib IIa 52 microarray gene expression 52 blinded randomized placebo controlled 52 pharmacokinetic characteristics 52 Phoenix NLME 52 CCR5 antagonist 52 multicentre randomized 52 farletuzumab 52 Panzem R NCD 52 Phase Ib II 52 CIMZIA TM certolizumab pegol 52 paclitaxel poliglumex 52 Blinatumomab 52 genotypic 52 quantitative gene expression 52 fidaxomicin Phase 3 52 NCT# ClinicalTrials.gov 52 temsirolimus Torisel ® 52 personalized dendritic 52 synDNA TM 52 Bayesian statistical 52 mertansine 52 forodesine 52 Apoptone 52 EOquin TM 52 busulfan 52 vitro cytotoxicity 52 liposome formulation 52 NN# [001] 51 Inhalation Solution 51 prospective multicentre 51 ceftazidime 51 nucleotide analog 51 Triapine R 51 GMX# 51 XTEN 51 inhaled AAT 51 evaluating REVLIMID 51 CLORETAZINE TM VNP#M 51 clevidipine 51 antimitotic 51 ascending dose 51 fosbretabulin 51 viral kinetic 51 genotypic resistance 51 selective modulator 51 OBPM 51 Safinamide 51 favorable tolerability 51 pharmacodynamic profile 51 investigational protease inhibitor 51 Azedra 51 histone deacetylase inhibitor 51 AIR# [001] 51 eliglustat tartrate 51 Abbott ARCHITECT 51 oral rivaroxaban 51 Secondary endpoints include 51 analgesic efficacy 51 Phase 2b Study 51 phase IIb III 51 MGd 51 rALLy clinical trial 51 therapeutic compound GAMMAGARD 51 intranasal delivery 51 EDEMA3 51 orally dosed 51 Genz # 51 Panzem NCD 51 ENDEAVOR III 51 teriflunomide 51 DAVANAT 51 BRIM2 51 flow cytometric 51 trastuzumab emtansine T DM1 51 MGN# 51 CRLX# 51 TAXUS VI 51 Antiviral Activity 51 selective androgen receptor modulator 51 randomized Phase III 51 lintuzumab 51 ENDEAVOR IV 51 NOXAFIL Oral Suspension 51 #T# L1 51 Histopathological 51 AEGR 51 Proellex TM 51 peptide conjugated 51 phase IIa 51 inhaled iloprost 51 Aplidin R 51 pharmacodynamic endpoints 51 Pharmacokinetic studies 51 TMC# C# 51 DermaVir Patch 51 DCCR 51 clinico pathological 51 trastuzumab DM1 T DM1 51 Phase 2a clinical 51 hemagglutination inhibition HAI 51 CD3 + 50 Tarceva TM 50 KRN# 50 davunetide intranasal AL 50 tumor histology 50 PERSEUS 50 phase IIb study 50 dose escalation phase 50 SUTENT ® 50 #nd EORTC NCI 50 cariprazine 50 AKT inhibitor 50 Phase 1b trial 50 ALB # 50 Archexin 50 Phase IIB 50 daily subcutaneous injections 50 multivariate statistical 50 HuMax EGFr 50 Phase Ia 50 preclinical pharmacology 50 Dual Opioid 50 SYNERGY Stent 50 TPI ASM8 50 BACcel 50 ritonavir boosted protease inhibitor 50 blinded randomized controlled 50 oxidative stress markers 50 pharmacokinetics 50 IIa clinical 50 TransVax ™ 50 DASISION 50 vidofludimus 50 Prodarsan ® 50 pharmacokinetic pharmacodynamic PK PD 50 stated Michelle Berrey 50 Phase Ib clinical 50 vivo toxicology 50 LibiGel Phase III 50 IFN α 50 PEG IFN 50 KN excels 50 Phase Ib study 50 XOMA 3AB 50 Cloretazine ® 50 CTA# 50 riociguat 50 Enhanze Technology 50 phase IIb clinical 50 ganetespib 50 cytotoxicity assays 50 nonclinical studies 50 Aspergillus nidulans 50 BIOV 50 highly immunogenic 50 Phase #/#a 50 potency selectivity 50 polyglutamate 50 PPAR gamma agonist 50 Aclidinium 50 multicenter randomized placebo controlled 50 Zybrestat 50 wilate ® 50 INCB# [001] 50 Vaxfectin R 50 IMPACT DCM 50 gp# protein [002] 50 Clinical Trial Results 50 rhLF 50 meta regression 50 UPLYSO 50 SUCCEED trial 50 Zenvia Phase III 50 Bruton tyrosine kinase Btk 50 ThermoDox ® clinical 50 metformin XR 50 LCP Tacro 49 Phase #b/#a 49 guanfacine extended release 49 TRANSFORMS 49 JVRS 49 ORAL Sync 49 BAL# [002] 49 MoxDuo ® IR 49 demonstrated clinically meaningful 49 tacrolimus ointment 49 safety tolerability pharmacokinetics 49 Spiegelmer ® 49 BLOSSOM 49 BrachySil TM 49 non nucleoside 49 bortezomib Velcade 49 radezolid 49 phase IIa clinical 49 prucalopride 49 small molecule agonists 49 IFN Beta 49 potently inhibits 49 ENMD # 49 tissue microarrays 49 bisulfite sequencing 49 Ophena TM 49 oral prodrug 49 tumor xenograft models 49 blinded randomized 49 TSQ Quantum 49 MetaCore TM 49 desvenlafaxine succinate 49 CLL8 49 vivo preclinical 49 PORxin 49 pharmacokinetic studies 49 APTIVUS 49 TQT 49 vivo pharmacology 49 Long Lesion 49 TIMP 1 49 paclitaxel Taxol ® 49 SAR# [004] 49 ABCSG 49 ALGRX 49 IIa trials 49 murine models 49 International SMI SYNN 49 Phase IIIb study 49 phase IIb 49 virus AAV 49 randomized multicenter Phase III 49 Folfox 49 efavirenz EFV 49 PNA FISH TM 49 RE LY ® 49 antiangiogenic therapy 49 ruxolitinib 49 ± SEM 49 ADVANCE PD 49 Phase 1b clinical 49 placebo controlled clinical 49 delipidation 49 biomarker validation 49 mg/m2 cohort 49 OMP #M# 49 Phase Ib Clinical Trial 49 DNA intercalator 49 Exherin TM 49 CC genotype 49 Phase Ib clinical trials 49 histone deacetylase HDAC inhibitor 49 Lucanix 49 pharmacokinetic PK profile 49 miRNA biomarkers 49 bortezomib Velcade R 49 placebo controlled Phase III 49 GLP toxicology studies 49 #:#-# [020] 49 genotyping arrays 49 administered subcutaneously 49 TOLAMBA 49 binds selectively 49 Capesaris 49 Omacetaxine mepesuccinate 49 CCX# 49 oral FTY# 49 H#N# VLP vaccine 49 SPIRIT FIRST 49 refractory prostate cancer 49 AST ALT 49 PrevOnco ™ 49 CEQ# 49 randomized Phase 2b 49 Histologic 49 elotuzumab 49 REVIVE TA 49 SynCon 49 omega interferon 49 low dose cytarabine 49 Multimeric 49 Interferon gamma 49 CARE HF 49 VNP#M 49 ART# 49 boosted protease inhibitor 49 ORAL Solo 49 Valortim ® 49 afamelanotide 49 PhysioLab 49 metabolomic 49 vinca alkaloid 49 torezolid phosphate 49 trivalent seasonal influenza 49 R#/MEM # 49 Topline Results 49 AVADO 49 pharmacokinetic profiles 49 Phase III psoriasis 49 phase 2a 49 phase IIb trial 49 Phase IIa clinical 49 ritonavir boosting 49 tumorigenicity 49 Meta analyzes 48 intranasal formulation 48 RezularTM 48 oral diclofenac 48 S/GSK# 48 active comparator 48 single ascending dose 48 Campath alemtuzumab 48 efficacy tolerability 48 ascending doses 48 tanespimycin 48 pharmacodynamic 48 Zoraxel 48 NEUGENE antisense 48 phenotyping 48 microdroplet based 48 EDEMA3 trial 48 blinded placebo controlled 48 4mg/kg 48 Aplidin 48 Flow cytometry 48 attain statistical significance 48 polymerase inhibitor 48 dacarbazine chemotherapy 48 tumor subtypes 48 cGMP manufacture 48 linear pharmacokinetics 48 HGS ETR1 48 bendamustine 48 ANCHOR trial 48 relapsed MCL 48 APEX AMI 48 AurSCOPE 48 tolerated dose MTD 48 estimated GFR 48 ASSERT trial 48 novel proprietary KL4 48 Phase 2b RESTORE CLI 48 microwell plate 48 CORE OM 48 Xanafide 48 randomized blinded 48 EGS# 48 plasma lipoprotein 48 Engerix B 48 Phase III ALLEGRO 48 Univariate 48 retrospective observational 48 tolevamer 48 GLYX 48 multiple logistic regression 48 nationally projectable 48 biostatistical 48 fluoropyrimidine 48 Onconase 48 Refiner MS 48 tipifarnib 48 MERLIN TIMI 48 Fc gamma receptor 48 RefSeq 48 synthetic siRNAs 48 PREVENT IV 48 IAP inhibitor 48 velafermin 48 Immunogenicity 48 ganaxolone 48 selective orally bioavailable 48 dosing cohorts 48 HCV SPRINT 48 HybSelect 48 Phase IIIB IV 48 Deadlinepix 48 APPRAISE 48 GLP toxicology 48 Secondary endpoints 48 human microdosing 48 florbetaben 48 masked placebo controlled 48 ACCEDE 48 nucleoside reverse transcriptase inhibitor 48 #dhTxB# 48 generalized estimating 48 PEG SN# 48 Histopathologic 48 subcutaneous SC 48 oral ferric iron 48 Novel Therapeutic 48 5 lipoxygenase activating 48 Forodesine HCl 48 #mg/day [001] 48 First Patient Enrolled 48 potently inhibited 48 tezampanel NGX# 48 Onrigin 48 N t RTIs 48 Micromet BiTE 48 cannabinor 48 inecalcitol 48 bicifadine 48 subcutaneous dosing 48 vemurafenib 48 liposomal doxorubicin 48 Rigorous scientific 48 alicaforsen enema 48 Androxal TM 48 confirmatory Phase IIIb 48 EndoTAG 48 CanAg 48 Cites Positive 48 PEG PAL 48 NICE SUGAR 48 BioMAP 48 FT IR spectroscopy 48 systemically administered 48 solithromycin 48 receptor inhibitor 48 VICTOR E1 48 PEGPH# 48 Sangamo ZFP TF 48 Teriflunomide 48 DLTs 48 Mantel Haenszel 48 randomized multicenter 48 delafloxacin 48 nonrandomized 48 APOPTONE 48 multiple ascending dose 48 pharmacophore 48 A3 adenosine receptor 48 cathepsin K inhibitor 48 vascular disrupting agents 48 USL# 48 intraperitoneally 48 Subgroup analysis 48 Cloretazine R 48 HIF PH inhibitors 48 achieved statistical significance 48 NIR spectroscopy 48 predictive biomarker 48 Aryplase 48 AVN# Phase 48 cobiprostone 48 ChIP chip 48 nanopharmaceutical 47 PROPEL trial 47 JAK inhibitor 47 QT QTc 47 Allovectin 7 ® 47 RE LY trial 47 multicenter Phase 47 PSN# [002] 47 label dose escalation 47 varespladib 47 prospectively defined 47 alpha pinene 47 eniluracil 47 beta2 agonist 47 poly ICLC 47 medicinal chemistry biology 47 PD LID 47 CBLC# 47 Subpart E 47 murine leukemia 47 lomitapide 47 VP# [004] 47 RoACTEMRA 47 Medidur TM FA 47 replicon 47 vitro ADMET 47 LCP AtorFen 47 ORMD 47 Sunesis Pharma 47 PROactive study 47 heavily pretreated 47 Plicera 47 Plenaxis TM 47 HCV replicon 47 doxorubicin docetaxel 47 dosage regimens 47 REVLIMID lenalidomide 47 ORENCIA ® 47 LB# [003] 47 xenograft models 47 flavopiridol 47 plasma pharmacokinetics 47 HBsAg 47 torezolid 47 Cloretazine R VNP#M 47 ON #.Na 47 LAF# 47 proteomic analyzes 47 Iloperidone 47 Zinc Finger 47 microdose 47 diabetic neuropathic pain 47 epigenetic therapies 47 Ness Ziona Israel 47 RGB # 47 clinical pharmacology studies 47 human tumor xenograft 47 Phase IIa trial 47 Cmax 47 pharmacokinetic profile 47 NOX E# 47 prasugrel Effient 47 fasting lipid 47 enzastaurin 47 temozolomide TMZ 47 vernakalant hydrochloride 47 gemcitabine Gemzar 47 CCR5 inhibitor 47 administered intraperitoneally 47 vitro toxicology 47 multicenter randomized Phase 47 maturation inhibitor 47 trastuzumab Herceptin ® 47 custom peptide synthesis 47 sunitinib malate 47 Secondary efficacy endpoints 47 ENRICH trial 47 LEXIVA r 47 CoFactor 47 lipopeptide 47 selectively activates 47 GelVac 47 #rd Annual CTRC 47 alpha 2a 47 zonisamide SR 47 Dr. Gabriel Lasala 47 nucleoside analog 47 Opterone 47 prospective randomized controlled 47 ICON7 47 PFO migraine 47 nab paclitaxel 47 PCI ExTRACT TIMI 47 Phase 2b clinical 47 TASKi2 47 noninferiority 47 intermittent dosing 47 bovine thrombin 47 MIRCERA 47 bioequivalency 47 Phase 1b clinical trials 47 rHuPH# 47 dose cohort 47 TRV# [001] 47 PS# [001] 47 IMPACT IMmunotherapy 47 ATL# [001] 47 BMS# 47 SUPER PET ® 47 GENOMICS 47 teduglutide 47 prognostic biomarker 47 immunogenicity 47 N glycan 47 docetaxel Taxotere R 47 EMRG VIO 47 CANCIDAS 47 Phase 2b kidney transplant 47 SBRB conducts these 47 posaconazole 47 Caliper LabChip 47 SPIRIT III 47 serum PTH 47 LT NS# 47 bivariate 47 PROTECT AF 47 AP Photo NAI# 47 maximal doses 47 Phase 2b study 47 PEARL SC 47 #th Annual Interscience 47 inhaled corticosteroid ICS 47 hemostatic efficacy 47 Prosaptide 47 visilizumab 47 Projected Release Date 47 randomized crossover 47 retrospective cohort 47 nucleoside nucleotide 47 FOSRENOL ® 47 R# #mg BID 47 eribulin mesylate 47 inhibitor RG# 47 Amrubicin 47 Immunoglobulin G 47 potent cytotoxic 47 YONDELIS 47 RNA amplification 47 sulodexide 47 Syllego system 47 mequinol 47 kinase profiling 47 Coremetrics Benchmark 47 Tracleer R 47 Intergroup Exemestane Study 47 subcutaneously injected 47 Ultrafast Insulin 47 NXL# 47 dose escalation trial 47 Posiphen 47 limiting generalizability 47 CAMMS# 47 TAXUS ATLAS 47 oxymorphone ER 47 serologic 47 WikiWealth.com s 47 OHR/AVR# 46 Exelixis compounds 46 AEG# 46 tolerability profiles 46 SABCS 46 deforolimus 46 Histological 46 transfection efficiency 46 mesalamine granules 46 peptide fragment 46 prospective observational studies 46 protease inhibitor PI 46 Phase III Clinical Trials 46 ELACYT 46 DMPK 46 peripheral blood mononuclear 46 transcriptome sequencing 46 leukotriene B4 46 Sym# 46 Inhibitor Human 46 picomolar 46 TG MV 46 linearly proportional 46 Multivariate logistic regression 46 interobserver 46 oral methylnaltrexone 46 Quantitative PCR 46 anti miRs antisense oligonucleotide 46 biochemistry physiology 46 univariate 46 Visit www.otc advisors.com 46 molecular biomarker 46 Corlux 46 pertuzumab 46 axitinib 46 Upregulation 46 antiviral efficacy 46 Panzem R 46 EINSTEIN DVT 46 GPI anchored 46 Inc. Nasdaq ALSE 46 porcine derived 46 statistically significant efficacy 46 NADiA 46 Phenyx 46 mapatumumab 46 Diamyd Medical Diamyd 46 beta. 46 genotype phenotype 46 PDE4 inhibitor 46 novel immunotherapeutic 46 insulin detemir 46 Scanning electron 46 asthma immunotherapeutic 46 Mathematical modeling 46 disease progression TTP 46 GLP1 agonist 46 intravenous dosing 46 effector function 46 Microarray analysis 46 perifosine KRX 46 ESBA# 46 Tamibarotene 46 pharmacoeconomic 46 biotherapeutic drugs 46 trodusquemine 46 PI3 kinase inhibitor 46 CRMD# 46 HCV polymerase inhibitor 46 pharmacokinetic properties 46 indibulin 46 CIMZIA TM 46 hematopoietic cancers 46 placebo controlled Phase 46 deoxy 46 PTH analogue 46 CaPre TM 46 PICM 46 potent antitumor activity 46 resolvin 46 using ImmunoGen TAP 46 IIb clinical trial 46 pharmacokinetic interactions 46 Phase #/#a trial 46 oral iron chelator 46 EOquin 46 therapeutically relevant 46 Carfilzomib 46 ClinProt 46 intravenously administered 46 ConclusionThis 46 physicochemical properties 46 peginesatide 46 ADCS ADL 46 Interferon alpha 46 Imprime PGG 46 μg kg 46 Altastaph 46 Serological 46 Elacytarabine 46 AeroLEF TM 46 HuCAL R 46 manually curated 46 Biomerk Tumorgrafts 46 antisense inhibitor 46 ancrod 46 XmAb# 46 DXL# 46 Elevated serum 46 PRT# 46 rhGH 46 IMC #B 46 RHUCIN 46 cRNA 46 www.thermo.com 46 OvaRex MAb 46 Further Validates 46 avosentan 46 retapamulin 46 Phase III placebo controlled 46 GeneICE 46 ISIS # 46 bicyclic 46 PhenoSense GT 46 alemtuzumab Campath 46 urate lowering 46 PREOS 46 SYMMETRY trial 46 MAP# 46 automated microscopy 46 DermaVir 46 Dasatinib 46 ZYBRESTAT 46 antifibrotic 46 gemcitabine carboplatin 46 Adrenergic 46 dosimetric 46 Clonicel 46 JAK2 inhibitors 46 subcutaneous formulation 46 potent antiviral 46 quadrivalent HPV vaccine 46 tumor specific antigen 46 Aurora kinase inhibitor 46 imetelstat 46 androgen receptor antagonist 46 MEND CABG 46 cystic fibrosis transmembrane 46 Preclinical studies suggest 46 NSCLC tumors 46 Vascular Biogenics 46 RSD# oral 45 Dynavax HBV vaccine 45 HCV RESPOND 2 45 fluticasone furoate 45 antiproliferative activity 45 gastric retentive 45 suppl. 45 virological response 45 glyco 45 Phenoptin 45 peginterferon alfa 2b 45 EGFR mutant 45 Tarvacin TM 45 biodistribution 45 CR# vcMMAE 45 GLPG# 45 Medidata Designer 45 Bevirimat 45 LEP ETU 45 randomized controlled clinical 45 Anticalins 45 Chenomx 45 Pharmacokinetics 45 gene expression assays 45 Panzem 45 EXPAREL ™ 45 immune modulating 45 anti leukemic 45 mg/m2 dose 45 siRNA duplexes 45 vitro experiments 45 eszopiclone 45 elacytarabine 45 BrachySil 45 INT# [002] 45 Phase #b/#a trial 45 TRO# 45 HTRF 45 chemometric 45 pivotal Phase III 45 huC# DM4 45 Immunohistochemical analysis 45 Phase IIb clinical 45 stochastic simulation 45 NOD SCID mice 45 interferon inducible 45 Zavesca R 45 novel prodrug 45 tecarfarin 45 carcinogenicity studies 45 DP b# 45 depsipeptide 45 VITAL Trial 45 microRNA biomarkers 45 Induced polarization 45 xenograft mouse 45 triacylglycerols 45 intraobserver 45 TPV r 45 immatics 45 serum cortisol 45 TG# [003] 45 dose regimens 45 CellCiphr 45 confidence intervals CIs 45 AvalonBay Communities Announces 45 potent inducer 45 Denufosol 45 Transfection 45 ViroMed 45 pramlintide metreleptin combination 45 DHPLC 45 CLIRS 45 trabectedin 45 thymidylate synthase TS 45 D glucan 45 Nasdaq NYMX 45 Phase 1b 45 mechanistic studies 45 mutational analysis 45 Multivariate 45 pegnivacogin 45 DAVANAT R exhibits 45 erythropoietic 45 NAMCS 45 proteomics metabolomics 45 Anthim 45 multiplexing capability 45 mucoregulator 45 IMC A# 45 Traficet EN